{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:31:15Z","timestamp":1755793875445,"version":"3.41.2"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>To achieve natural-looking outcomes when treating dynamic lines with botulinum toxin (BoNT), retreatment must be timed such that the patient maintains a relatively constant aesthetic outcome. Although first-generation BoNT products require retreatment with 3- to 4-month frequency to avoid discontinuous correction, the average patient returns for treatment every 6 months, when these toxins have generally fully worn off.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To discuss the number of days a typical patient treated with daxibotulinumtoxinA for injection (DAXI) or legacy BoNT products will spend undertreated or uncorrected in a given calendar year.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>Median time for maintaining glabellar lines in the \u201cnone\u201d or \u201cmild\u201d severity range was compared for approved doses of onabotulinumtoxinA (ONA; 120 days) and DAXI (168 days).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>The average patient treated with 40U of DAXI every 6 months can expect to be uncorrected (with \u201cmoderate\u201d or \u201csevere\u201d glabellar lines) for 14.5 days between visits compared with 61.5 days for 20U of ONA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>An extended duration BoNT product can be expected to create greater consistency in aesthetic outcome and minimize the discontinuous correction commonly seen with first-generation BoNT products for patients treated twice a year, without requiring a change in patient behavior regarding visit frequency.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000003852","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T17:00:13Z","timestamp":1688058013000},"page":"862-864","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Bridging the Gap: Sustained Treatment Effect of Glabellar Lines With Twice-A-Year Treatment With DaxibotulinumtoxinA"],"prefix":"10.1097","volume":"49","author":[{"given":"Jeffrey S.","family":"Dover","sequence":"first","affiliation":[{"name":"SkinCare Physicians, Chestnut Hill, Massachusetts;"},{"name":"Dermatology, Yale University School of Medicine, New Haven, Connecticut;"},{"name":"Dermatology, Brown Medical School, Providence, Rhode Island;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nowell","family":"Solish","sequence":"additional","affiliation":[{"name":"Dermatology at the University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd M.","family":"Gross","sequence":"additional","affiliation":[{"name":"Data Science and Interim Head of Clinical Development at Revance Therapeutics Inc., Nashville Tennessee;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conor J.","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Medical Affairs and Scientific Innovation at Revance Therapeutics Inc., Nashville, Tennessee;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Brown","sequence":"additional","affiliation":[{"name":"Medical Affairs, at Revance Therapeutics, Inc., Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaad.2019.06.1313","article-title":"DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"82","author":"Bertucci","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1111\/j.1524-4725.2012.02582.x","article-title":"OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines","volume":"38","author":"Glogau","year":"2012","journal-title":"Dermatol Surg"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/asj\/sjac157","article-title":"Safety, pharmacodynamic response, and treatment satisfaction with OnabotulinumtoxinA 40 U, 60 U, and 80 U in subjects with moderate to severe dynamic glabellar lines","volume":"42","author":"Joseph","year":"2022","journal-title":"Aesthet Surg J"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"ojab036","DOI":"10.1093\/asjof\/ojab036","article-title":"High-dose neuromodulators: a roundtable on making sense of the data in real-world clinical practice","volume":"3","author":"Fabi","year":"2021","journal-title":"Aesthet Surg J Open Forum"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/toxins10120535","article-title":"AbobotulinumtoxinA (Dysport\u00ae), onabotulinumtoxinA (Botox\u00ae), and incobotulinumtoxinA (Xeomin\u00ae) neurotoxin content and potential implications for duration of response in patients","volume":"10","author":"Field","year":"2018","journal-title":"Toxins (Basel)"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:01:42Z","timestamp":1753999302000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":5,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000003852","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"type":"print","value":"1076-0512"},{"type":"electronic","value":"1524-4725"}],"subject":[],"published":{"date-parts":[[2023,6,22]]}}}